EBV特异性细胞毒性T淋巴细胞：一种免疫治疗模型。
EBV specific CTL: a model for immune therapy.
作者信息
Rooney C M, Heslop H E, Brenner M K
机构信息
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA.
出版信息
Vox Sang. 1998;74 Suppl 2:497-8. doi: 10.1111/j.1423-0410.1998.tb05463.x.
We have been generating Epstein-Barr virus specific cytotoxic T cells for patients at high risk of developing EBV driven lymphoma. To discover the fate of the cells in vivo, we first marked them genetically, using a retroviral vector. Our results in 51 patients show that the approach is safe, that the CTL persist for several years and that they are able to mediate anti-viral and anti-tumor effects. We are now studying other virally-linked malignancies to discover whether a similar approach will be of therapeutic value.
我们一直在为有发展成爱泼斯坦-巴尔病毒驱动淋巴瘤高风险的患者生成爱泼斯坦-巴尔病毒特异性细胞毒性T细胞。为了在体内发现这些细胞的命运，我们首先使用逆转录病毒载体对它们进行基因标记。我们对51名患者的研究结果表明，该方法是安全的，细胞毒性T淋巴细胞（CTL）可以持续数年，并且它们能够介导抗病毒和抗肿瘤作用。我们现在正在研究其他与病毒相关的恶性肿瘤，以发现类似的方法是否具有治疗价值。
Zotero 插件